

## **Bis-Ketol Nucleoside Triesters as Prodrugs of the Antiviral Nucleoside Triphosphate Analogues of 3'-Deoxythymidine and 3'-Deoxy-2',3'-didehydrothymidine**

**Kim C. Calvo,\* Xiaohong Wang, and Gerald F. Koser**

Department of Chemistry, The University of Akron, Akron, Ohio, USA

### **ABSTRACT**

Derivatives of 3'-deoxythymidine (ddT) and 3'-deoxy-2',3'-didehydrothymidine (d4T) were prepared in which the 5'-hydroxyl group of the nucleoside was esterified to a bis-ketol phosphate. The resulting phosphate triesters are postulated to be prodrugs of the corresponding 5'-mononucleotides, which are formed intracellularly by the hydrolysis of the two ketol ester groups. The triesters were tested for anti-HIV activity with the result that those derived from ddT showed enhanced antiviral activity when compared to the parent nucleoside.

*Key Words:* Bis-ketol; Triesters; Prodrugs; Triphosphate; Didehydrothymidine.

### **INTRODUCTION**

Analogs of deoxyribonucleosides and nucleotides find use as antiviral compounds.<sup>[1–4]</sup> They constitute one of the important components of the combination therapy currently used in the treatment of AIDS.<sup>[5]</sup> These nucleoside analogs are really prodrugs of the biologically active form, the 5'-triphosphate,<sup>[6]</sup> which inhibits viral replication by interaction with the viral reverse transcriptase. The nucleoside analogs


---

\*Correspondence: Kim C. Calvo, Ph.D., Department of Chemistry, The University of Akron, Akron, OH 44325-3601, USA; Fax: (330) 972-7370; E-mail: kimcalvo@uakron.edu.


are converted to the active triphosphate form by three successive phosphorylation reactions catalyzed by various cellular kinases. Several nucleoside analogs, which are capable of potent inhibition of reverse transcriptase when present as the triphosphate form, do not show antiviral activity in screening assays because they are poor substrates for the cellular kinases.<sup>[7]</sup> The mono-, di- or triphosphate forms of the nucleosides are too polar to pass through the cell membrane and so cannot be used as drugs.

McGuigan has examined a strategy, named the kinase bypass, which attempts to circumvent the first phosphorylation reaction needed to activate all nucleoside analog prodrugs.<sup>[8-12]</sup> In this strategy, the double negative charge associated with a nucleoside analog monophosphate is masked by forming a nucleoside analog monophosphate triester. The triester is sufficiently lipophilic that it is able to penetrate the cell membrane. Related strategies include the use of a bis-S-acyl-2-thioethyl ester<sup>[13]</sup> and the use of the bis-pivaloyloxymethyl ester.<sup>[14]</sup> It appears that by judicious choice of the alcohols used in triester formation, it should be possible to direct intracellular hydrolysis to form the nucleoside analog monophosphate. The alcohols incorporated into the triester group should allow rapid triester hydrolysis to the diester monoanion, which should be retained within the cell since it is too polar to pass through the membrane, and subsequently to the monoester dianion. In addition, hydrolysis of the triester and diester should occur in a way that leads to formation of the nucleoside analog monophosphate, and not to the original nucleoside.

The ketol esters of phosphoric acid satisfy both of these criteria. The rate constant for the hydrolysis of a bis-ketol alkyl phosphate triester is about  $6.2 \times 10^{-4} \text{ s}^{-1}$  at pH 7.4 and 37°C, giving a half life for the triester of about 19 min.<sup>[15]</sup> In addition, the mechanism for the hydrolysis as given in Scheme 1, demands that the ketol group must always be lost during hydrolysis to the diester.<sup>[16]</sup> Pseudorotation of the intermediate phosphorane places the alcohol oxygen of the ketol in the apical position. After the ketol ester group is expelled, the phosphorylated carbonyl hydrate eliminates the phosphate diester. Once the diester is formed, two hydrolysis reactions are possible.



**Scheme 1.** Mechanism of base hydrolysis of ketol phosphate triesters.



**Scheme 2.** Proposed routes for intracellular hydrolysis of mono-ketol phosphate diesters.

The monoketol diester can either hydrolyze non-enzymatically and regioselectively via phosphate elimination from the ketol<sup>[17]</sup> to give the nucleoside monophosphate or enzymatically to produce either the nucleoside monophosphate and the ketol, or the ketol phosphate and the nucleoside analog (Scheme 2). Hydrolysis to give the ketol phosphate does not accomplish the kinase bypass.

In this paper we describe the synthesis of various bis-ketol ddT and d4T triesters and the results of antiviral screening of the compounds.

## EXPERIMENTAL

**General.** NMR spectra were recorded on a Varian 300 MHz NMR. The chemical shifts for  $^1\text{H}$  spectra are referenced to the residual protio form of the deuterated NMR solvent. The chemical shifts for  $^{13}\text{C}$  spectra are referenced to the solvent carbons, while the  $^{31}\text{P}$  NMR shifts (proton-decoupled) are referenced to external 85% phosphoric acid capillary in the NMR solvent. Reagents were obtained from Aldrich, Lancaster or Acros. Solvents used in reactions were purified by standard methods by distillation from appropriate drying agents. The ddT was prepared by literature procedures.<sup>[18]</sup>

**Tris-Ketol Phosphoric Acid Esters (1a–c).** These compounds were prepared by treatment of crystalline phosphoric acid with 3 mole equivalents of  $\text{PhI}(\text{OAc})_2$  and 6 to 6.5 mole equivalents of the appropriate silyl enol ethers in *t*-butyl alcohol as reported in<sup>[19]</sup> for the analogous procedure with *p*-(difluoroiodo)toluene. Beginning with  $\text{H}_3\text{PO}_4$  (10.0 mmol for **1a**, 15.3 mmol for **1b**, and 25.5 mmol for **1c**), the product yields were **1a** (22%, mp 107–9°C), **1b** (44%, mp 43–44°C), and **1c** (56%, mp 142–4°C). Selected NMR data ( $^1\text{H}$ ,  $^{13}\text{C}$ , and  $^{31}\text{P}$ ) for **1a** and **1c** are reported in.<sup>[19]</sup>

**Lithium Bis-Ketol Phosphate Diesters (2a–c).** These compounds were prepared as described in<sup>[19]</sup> Solutions of the tris-ketol phosphates [**1a** (5.89 mmol), **1b** (3.90 mmol), and **1c** (3.49 mmol)] and LiBr (1 to 1.3 equivalents) in dry acetone (120 or 130 mL) were stirred and heated under reflux (3 to 5 hr). During this time, the



lithium bis-ketol phosphates precipitated and were isolated by filtration: yields; **2a** (89%, mp 221–2°C), **2b** (93%, mp 214–6°C), and **2c** (100%, mp 189–93°C). Selected NMR data (<sup>1</sup>H, <sup>13</sup>C, and <sup>31</sup>P) for **2a** and **2c** are reported in.<sup>[19]</sup> Combustion analysis of samples of **2a–2c**, previously prepared in our laboratory, indicate that these compounds may be hemi-hydrates.<sup>[19]</sup>

**Bis-Ketol Hydrogen Phosphoric Acid Diesters (3a-c).** Mixtures of the lithium bis-ketol phosphates [**2a** (2.57 mmol), **2b** (2.00 mmol), and **2c** (1.35 mmol)] and Dowex (50w × 8, H<sup>+</sup> form) ion exchange resin [14 g for **2a**, 7 g for **2b** and **2c**] in acetonitrile (50 mL) were stirred and heated under reflux for 3 h. The salts dissolved as they were converted to **3**. The resin was then removed by filtration and washed with methylene chloride (2 × 20 mL). Concentration of the filtrate and washings gave white solids, identified as **3a** (89%, mp 105–7°C), **3b** (90%, mp 72–4°C), and **3c** (92%).

**4b-3'-Deoxythymidine-5'-bis(heptanoylmethyl)phosphate.** Dicyclohexylcarbodiimide (DCC, 0.660 g, 3.20 mmol) was added at rt to a stirred solution of the bis-ketol hydrogen phosphate **3b** (0.561 g, 1.60 mmol) in dry CH<sub>2</sub>Cl<sub>2</sub> (10 mL); a white solid (dicyclohexyl urea) separated immediately. After 4 h, the mixture was passed through a pipet packed with a glass wool plug. Triethylamine (25 drops) and ddT (91 mg, 0.40 mmol) were added to the filtrate, and the reaction mixture was allowed to stir for 20 h at rt. The solvent was then removed (rotary evaporator), and the residual yellow oil was subjected to flash column chromatography on silica gel (20 g) with CHCl<sub>3</sub> (300 mL), CHCl<sub>3</sub>/CH<sub>3</sub>OH (200:1 (v/v), 100 mL), CHCl<sub>3</sub>/CH<sub>3</sub>OH (100:1 (v/v), 100 mL), and CHCl<sub>3</sub>/CH<sub>3</sub>OH (75:1 (v/v), 150 mL) to give **4b** as a pale yellow oil which gradually (1 week) solidified under mechanical vacuum; white solid; yield 202 mg (90%); mp 51.5–53°C. <sup>1</sup>H NMR (CDCl<sub>3</sub>): 0.88 (t, J = 6.9 Hz, 6H), 1.28 (m, 12H), 1.61 (m, 4H), 1.93 (d, J = 1.1 Hz, 3H), 2.01–2.18 (m, 3H), 2.38–2.46 (m, 5H), 4.28–4.54 (m, 3H), 4.63–4.82 (m, 4H), 6.11–6.15 (m, 1H), 7.54 (d, J = 1.1 Hz, 1H), 8.50 (br s, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 12.60, 14.22, 22.65, 23.39, 25.56, 28.99, 31.69, 32.21, 38.60, 68.98 (d, J<sub>CP</sub> = 5.4 Hz), 71.16 (t, J<sub>CP</sub> = 5.1 Hz), 78.79 (d, J<sub>CP</sub> = 8.5 Hz), 86.14, 110.96, 135.86, 150.42, 163.78, 204.05 (t, J<sub>CP</sub> = 3.8 Hz). <sup>31</sup>P NMR (CDCl<sub>3</sub>): 0.009 (s). IR (neat): 1694 cm<sup>-1</sup> (C = O), 1270 cm<sup>-1</sup> (P = O). Anal. Calcd. for C<sub>26</sub>H<sub>43</sub>N<sub>2</sub>O<sub>9</sub>P; C, 55.90; H, 7.76; N, 5.01. Found: C, 56.19; H, 7.99; N, 5.10.

**4a-3'-Deoxythymidine-5'-bis(2,2-dimethylpropanoylmethyl)phosphate.** Yield 221 mg (88%). <sup>1</sup>H NMR (CDCl<sub>3</sub>): 1.19 (d, J = 2.1 Hz, 18H), 1.93 (d, J = 1.0 Hz, 3H), 2.02–2.15 (m, 3H), 2.35–2.44 (m, 1H), 4.29–4.59 (m, 3H), 4.89–5.11 (m, 4H), 6.13–6.16 (m, 1H), 7.58 (d, J = 1.1 Hz, 1H), 8.15 (br s, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>): 12.58, 25.53, 26.35, 32.26, 42.87, 68.03 (dd, J<sub>CP</sub> = 5.3 Hz), 68.83 (d, J<sub>CP</sub> = 5.5 Hz), 78.85 (d, J<sub>CP</sub> = 7.3 Hz), 86.05, 110.92, 135.96, 150.50, 163.90, 208.16 (t, J<sub>CP</sub> = 3 Hz). <sup>31</sup>P NMR (CDCl<sub>3</sub>): 0.46 (s). mp: 114–115°C. IR (neat): 1695 cm<sup>-1</sup> (C = O), 1270 cm<sup>-1</sup> (P = O). Anal. Calcd. for C<sub>22</sub>H<sub>35</sub>N<sub>2</sub>O<sub>9</sub>P; C, 52.59; H, 7.02; N, 5.57. Found: C, 52.54; H, 7.04; N, 5.59.

**4c-3'-Deoxythymidine-5'-bis(phenacyl)phosphate.** Yield 153 mg (88%). <sup>1</sup>H NMR (CDCl<sub>3</sub>): 1.90 (d, J = 0.9 Hz, 3H), 2.03–2.19 (m, 3H), 2.36–2.46 (m, 1H), 4.32–4.42 (m, 1H), 4.46–4.68 (m, 2H), 5.41–5.61 (m, 4H), 6.12–6.16 (m, 1H), 7.48–7.55 (m,



4H), 7.58–7.68 (m, 2H), 7.87–7.93 (m, 4H), 8.65 (br s, 1H).  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ): 12.57, 25.61, 32.18, 69.14 (d,  $J_{\text{CP}} = 6.0$  Hz), 69.73 (dd,  $J_{\text{CP}} = 6.4$  Hz), 78.79 (d,  $J_{\text{CP}} = 8.5$  Hz), 86.06, 111.02, 127.90, 129.21, 133.93, 134.41, 135.89, 150.45, 163.77, 192.32 (t,  $J_{\text{CP}} = 3.7$  Hz).  $^{31}\text{P}$  NMR ( $\text{CDCl}_3$ ): 0.52 (s). mp: 58–59°C. IR (neat): 1690  $\text{cm}^{-1}$  (C = O), 1266  $\text{cm}^{-1}$  (P = O). Anal. Calcd. for  $\text{C}_{26}\text{H}_{27}\text{N}_2\text{O}_9\text{P}\cdot\frac{1}{2}\text{H}_2\text{O}$ ; C, 56.62; H, 5.12; N, 5.08. Found: C, 56.63; H, 5.12; N, 5.08.

**5b-3'-Deoxy-2',3'-didehydrothymidine-5'-bis(heptanoylmethyl)phosphate.** DCC (1.41 g, 6.83 mmol) was added at rt to a stirred solution of **3b** (1.20 g, 3.42 mmol) in dry  $\text{CH}_2\text{Cl}_2$  (15 mL); a white solid separated immediately. After 5h, the mixture was passed through a pipet packed with a glass wool plug. Triethylamine (25 drops) and d4T (0.192 g, 0.86 mmol) were added to the filtrate and the reaction mixture was allowed to stir for 2–3 days at rt. The solvent was then removed and the residual yellow oil was subjected to flash column chromatography on silica gel (26 g) with  $\text{CHCl}_3$  (300 mL),  $\text{CHCl}_3/\text{CH}_3\text{OH}$  (200:1 (v/v), 100 mL),  $\text{CHCl}_3/\text{CH}_3\text{OH}$  (100:1 (v/v), 100 mL), and  $\text{CHCl}_3/\text{CH}_3\text{OH}$  (75:1 (v/v), 150 mL) to give **5b** as a pale yellow oil which gradually solidified (1 week) under mechanical vacuum. yield 320 mg (67%). Further purification of this material by a second chromatography on silica gel (6 g) with  $\text{CHCl}_3$  (150 mL) and  $\text{CHCl}_3/\text{CH}_3\text{OH}$  (200:1 (v/v), 150 mL) returned 0.280 g of **5b**. mp: 90–92°C.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 0.88 (t,  $J = 7.0$  Hz, 6H), 1.21–1.28 (m, 12H), 1.54–1.64 (m, 4H), 1.89 (d,  $J = 1.2$  Hz, 3H), 2.38–2.42 (m, 4H), 4.35–4.52 (m, 2H), 4.60–4.83 (m, 4H), 4.99–5.06 (m, 1H), 5.86–5.92 (m, 1H), 6.39–6.42 (m, 1H), 7.01–7.04 (m, 1H), 7.36 (d,  $J = 1.2$  Hz, 1H), 8.82 (br s, 1H).  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ): 12.39, 14.19, 22.61, 23.37, 28.96, 31.66, 38.55, 68.37 (d,  $J_{\text{CP}} = 6.1$  Hz), 71.07 (dd,  $J_{\text{CP}} = 6.1$  Hz), 84.78 (d,  $J_{\text{CP}} = 8.6$  Hz), 89.77, 111.46, 127.58, 133.40, 136.28, 151.03, 163.96, 203.92 (t,  $J_{\text{CP}} = 4.8$  Hz).  $^{31}\text{P}$  NMR ( $\text{CDCl}_3$ ): -0.15 (s). IR (neat): 1699  $\text{cm}^{-1}$  (C = O), 1265  $\text{cm}^{-1}$  (P = O). Anal. Calcd. for  $\text{C}_{26}\text{H}_{41}\text{N}_2\text{O}_9\text{P}$ ; C, 56.11; H, 7.42; N, 5.03. Found: C, 56.32; H, 7.08; N, 5.31.


**5a-3'-Deoxy-2',3'-didehydrothymidine-5'-bis(2,2-dimethylpropanoylmethyl)phosphate.** Yield 300 mg (66%).  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.18 (d,  $J = 3.5$  Hz, 18H), 1.90 (d,  $J = 1.2$  Hz, 3H), 4.37–4.57 (m, 2H), 4.83–5.12 (m, 5H), 5.87–5.91 (m, 1H), 6.42–6.46 (m, 1H), 7.04–7.07 (m, 1H), 7.40 (d,  $J = 1.2$  Hz, 1H), 8.55 (br s, 1H).  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ): 12.36, 26.35, 42.87, 67.93 (dd,  $J_{\text{CP}} = 4.8$  Hz), 68.26 (d,  $J_{\text{CP}} = 6.1$  Hz), 84.90 (d,  $J_{\text{CP}} = 8.6$  Hz), 89.74, 111.43, 127.40, 133.64, 136.47, 150.97, 163.88, 208.15 (t,  $J_{\text{CP}} = 3$  Hz).  $^{31}\text{P}$  NMR ( $\text{CDCl}_3$ ): 0.22 (s). mp: 121–122°C. IR (neat): 1700  $\text{cm}^{-1}$  (C = O), 1262  $\text{cm}^{-1}$  (P = O). Anal. Calcd. for  $\text{C}_{22}\text{H}_{33}\text{N}_2\text{O}_9\text{P}$ ; C, 52.80; H, 6.65; N, 5.60. Found: C, 53.06; H, 6.84; N, 5.85.

**5c-3'-Deoxy-2',3'-didehydrothymidine-5'-bis(phenacyl)phosphate.** Yield 310 mg (87%).  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ): 1.89 (d,  $J = 1.1$  Hz, 3H), 4.48–4.68 (m, 2H), 5.05–5.15 (m, 1H), 5.37–5.61 (m, 4H), 5.89–5.92 (m, 1H), 6.47–6.51 (m, 1H), 7.04–7.08 (m, 1H), 7.44 (d,  $J = 1.3$  Hz, 1H), 7.48–7.54 (m, 4H), 7.60–7.67 (m, 2H), 7.86–7.92 (m, 4H), 8.56 (br s, 1H).  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ ): 12.39, 68.48 (d,  $J_{\text{CP}} = 6.1$  Hz), 69.64 (dd,  $J_{\text{CP}} = 5.3$  Hz), 84.89 (d,  $J_{\text{CP}} = 8.5$  Hz), 89.74, 111.48, 127.49, 127.86, 129.21, 133.58, 133.84, 134.42, 136.39, 151.00, 163.91, 192.24 (t,  $J_{\text{CP}} = 4.2$  Hz).  $^{31}\text{P}$  NMR ( $\text{CDCl}_3$ ): 0.29 (s). mp: 72–74°C. IR (neat): 1703  $\text{cm}^{-1}$  (C = O), 1102  $\text{cm}^{-1}$  (P = O). Anal. Calcd. for  $\text{C}_{26}\text{H}_{25}\text{N}_2\text{O}_9\text{P}\cdot\frac{1}{2}\text{H}_2\text{O}$ ; C, 56.83; H, 4.77; N, 5.10. Found: C, 56.94; H, 4.68; N, 5.15.



**Hydrolysis rate constant for 5c:** The hydrolysis of 5c was determined as indicated in reference 8. At 25°C, pH 7.68, the hydrolysis rate constant is 0.0260 min<sup>-1</sup>. Using an activation energy of 18.40 kcal/mole,<sup>[15]</sup> we estimate that at pH 7.4 and 37°C, the half life of 5c is about 42 min.

**Assay of anti-HIV activity:** The bis-ketol ddT and d4T derivatives were tested for anti-HIV activity at the National Cancer Institute by their standard protocol.<sup>[20]</sup> In this protocol, the compounds are dissolved in DMSO and then serially diluted into the cell culture medium. CEM cells are used as the T4 lymphocytes. These cells are added to the culture medium followed by HIV-1. An uninfected control in the presence of the compound being tested is used as a toxicity control, and infected and uninfected cells without the compound serve as basic controls. Cell viability is assessed by the formazan color development following addition of the tetrazolium salt, XTT. The IC<sub>50</sub> values represent the molar concentration of compound that results in 50% inhibition of



**Scheme 3.** Synthesis of bis-ketol phosphate derivatives of deoxy and dideoxythymidine.



uninfected cell growth. The EC<sub>50</sub> values represent the molar concentration of compound that results in survival of 50% of infected cells. The TI<sub>50</sub> is the ratio of IC<sub>50</sub>/EC<sub>50</sub>.

## RESULTS AND DISCUSSION

The synthesis of the bis-ketol ddT and d4T monophosphate triesters was accomplished by phosphorylation of the nucleoside with the tetra-kis ketol pyrophosphates generated in situ from bis-ketol hydrogen phosphates and DCC, Scheme 3. Formation of the bis-ketol hydrogen phosphates was made possible by using an ion exchange resin to exchange lithium for proton. The formation of the lithium bis-ketol phosphates proceeded almost quantitatively from the tris-ketol phosphates using LiBr in acetone. Overall, the synthesis proceeded in good yield from the nucleoside derivative to give the desired bis-ketol phosphate triesters.

Table 1 summarizes the in vitro anti-HIV test results for the bis-ketol phosphate triesters of ddT and d4T given in Scheme 4. In the assay conducted by the NCI, ddT is classified as inactive in inhibiting the growth of HIV in CEM T4 lymphocytes. This category is reserved for compounds showing an EC<sub>50</sub> greater than about 200  $\mu$ M. When the bis-ketol phosphate is added to the 5-hydroxyl of ddT, all of the derivatives become moderately active in inhibiting the growth of HIV. The EC<sub>50</sub> values for the bis-ketol phosphate ddT triesters ranged from 19 to 25  $\mu$ M which represents a decrease in EC<sub>50</sub> of at least 10 fold (the NCI assay did not always determine the higher limit of activity) when compared to the parent ddT. This increase in anti-viral activity is attributed to the formation of increased levels of the monophosphate of ddT in the cells.

**Table 1.** Anti-HIV activity of compounds **4a–c** and **5a–c**.<sup>a</sup>

Compound	IC <sub>50</sub> <sup>b</sup> $\mu$ M	EC <sub>50</sub> <sup>c</sup> $\mu$ M	TI <sub>50</sub> <sup>d</sup>
ddT	> 200	INACTIVE <sup>e</sup>	
<b>4a</b>	> 200	23.	> 8.7
<b>4b</b>	> 200	19.	> 10
<b>4c</b>	> 200	25.	> 8
d4T	> 200	0.60	333
<b>5a</b>	> 200	1.3	> 154
<b>5b</b>	> 180	0.51	> 353
<b>5c</b>	110	0.89	124

<sup>a</sup>Compounds were tested against HIV-1 in CEM cells according to the NCI protocol.<sup>[20]</sup>


<sup>b</sup>Concentration that gives a cell growth of 50% relative to a culture not exposed to the compound or virus.

<sup>c</sup>Concentration that leads to 50% protection of virus infected cells.

<sup>d</sup>The ratio IC<sub>50</sub>/EC<sub>50</sub>.

<sup>e</sup>According to the National Cancer Institute, the EC<sub>50</sub> of this compound is greater than 200  $\mu$ M and the compound is labeled as inactive. Compounds **4a–c** are labeled moderately active. Compounds **5a–c** are all labeled as active by the NCI.





R = *t*-butyl (a), hexyl (b), phenyl (c)

**Scheme 4.** Structural formulas of nucleotides tested for anti-HIV activity.

Both ddT and d4T have been assayed for anti-HIV activity in the past. When ddT and d4T were examined in the same assay system and the data reported in the same paper,<sup>[21,22]</sup> ddT was found to have an EC<sub>50</sub> about 20 times larger than d4T. When the triphosphates of ddT and d4T were analyzed as inhibitors of HIV reverse transcriptase using the same enzyme and the same polymeric substrate,<sup>[23]</sup> the inhibition constant for ddT was about 3 times that for d4T. It is clear that both ddT and d4T are active against HIV in an *in vitro* assay or reverse transcriptase assay. The fact that d4T is only three times better at inhibiting reverse transcriptase but 20 fold better at protecting cells from HIV indicates that the two compounds lead to significantly different levels of triphosphate inside the cells when administered as the nucleosides. The data on the EC<sub>50</sub> values of the bis-ketol phosphate triesters of ddT and d4T in this study indicate that the bis-ketol derivatives of d4T inhibit HIV at concentrations about 25 fold lower than the bis-ketol derivatives of ddT. However, in the assay used to assess anti-HIV activity, the EC<sub>50</sub> of d4T is about 300 fold lower than the EC<sub>50</sub> of ddT. The addition of the bis-ketol phosphate group to ddT has decreased the EC<sub>50</sub> value by at least 10 fold. Although the addition of a bis-ketol triester to d4T did not significantly improve the EC<sub>50</sub>, it did not render the nucleoside analog inactive. This is in contrast to a series of bis-ketol phosphate AZT derivatives that were tested previously<sup>[24]</sup> where the bis-ketol derivative was 1.5 to 77 times more active than the parent nucleoside analog. In the case of ddT, the addition of a bis-ketol triester significantly improved the EC<sub>50</sub> value. The bis-ketol phosphate triesters of ddT behave as though they were pro-drugs of ddT monophosphate esters.

#### ACKNOWLEDGMENT

This research was supported in part by NIH grant AI043975 awarded to G.F. Koser and K.C. Calvo.

#### REFERENCES

1. Robins, R.K. The potential of nucleotide analogs as inhibitors of retroviruses and tumors. *Pharm. Res.* **1984**, *1*, 11–18.



2. DeClercq, E. Recent advances in the search for selective antiviral agents. *Adv. Drug Res.* **1990**, *17*, 1–59.
3. Herdewijn, P.A.M.M. Novel nucleoside strategies for anti-HIV and anti-HSV therapy. *Antivir. Res.* **1992**, *19*, 1–14.
4. *Nucleosides and Nucleotides as Antitumor and Antiviral Agents*; Chu, C.D., Baker, D.C., Eds.; Plenum Press: New York, 1993.
5. DeClercq, E. Antiviral therapy for human immunodeficiency virus infections. *Clin. Microbiol. Rev.* **1995**, *8*, 200–239.
6. Jones, R.J.; Bischofberger, N. Minireview: nucleotide prodrugs. *Antivir. Res.* **1995**, *27*, 1–17.
7. Hao, Z.; Cooney, D.A.; Farquhar, D.; Perno, C.F.; Zhang, K.; Masood, R.; Wilson, Y.; Hartman, N.R.; Balzarini, J.; Johns, D.G. Potent DNA chain termination activity and selective inhibition of human immunodeficiency virus reverse transcriptase by 2',3'-dideoxyuridine-5'-triphosphate. *Mol. Pharmacol.* **1990**, *37*, 157–163.
8. McGuigan, C.; Tollerfield, S.M.; Riley, P.A. Synthesis and biological evaluation of some phosphate triester derivatives of the anti-viral drug AraA. *Nucleic Acids Res.* **1989**, *17*, 6065–6075.
9. McGuigan, C.; O'Connor, J.J.; Nicholls, S.R.; Nickson, C.; Kinchington, D. Synthesis and anti-HIV activity of some novel substituted dialkyl phosphate derivatives of AZT ddCyd. *Antivir. Chem. Chemother.* **1990**, *1*, 355–360.
10. McGuigan, C.; Pathirana, R.N.; Mahmood, N.; Devine, K.G.; Hay, A.J. Aryl phosphate derivatives of AZT retain activity against HIV1 in cell lines which are resistant to the action of AZT. *Antivir. Res.* **1992**, *17*, 311–321.
11. McGuigan, C.; Pathirana, R.N.; Balzarini, J.; DeClercq, E. Intracellular delivery of bioactive AZT nucleotides by aryl phosphate derivatives of AZT. *J. Med. Chem.* **1993**, *36*, 1048–1052.
12. McGuigan, C.; Kinchington, D.; Wang, M.F.; Nicholls, S.R.; Nickson, C.; Galpin, S.; Jeffries, D.J.; O'Connor, J.J. Nucleoside analogs previously found to be inactive against HIV may be activated by simple chemical phosphorylation. *FEBS Lett.* **1993**, *322*, 249–252.
13. Thumann-Schweitzer, C.; Gosselin, G.; Perigaud, C.; Benzaria, S.; Girardet, J.L.; Lefebvre, I.; Imbach, J.L.; Kirn, A.; Aubertin, A.M. Anti-human immunodeficiency virus type 1 activities of dideoxynucleoside phosphotriester derivatives in primary monocytes/ macrophages. *Res. Virol.* **1996**, *147*, 155–163.
14. Farquhar, D.; Khan, S.; Srivastva, D.N.; Saunders, P.P. Synthesis and antitumor evaluation of bis[(pivaloyloxy)methyl]2'-deoxy-5-fluorouridine 5'-monophosphate (FdUMP): a strategy to introduce nucleotides into cells. *J. Med. Chem.* **1994**, *37*, 3902–3909.
15. Calvo, K.C.; Moore, R.G.; Koser, G.F. Bis-ketol phosphate alkyl triesters: rate of initial ketol group hydrolysis. *Tetrahedron Lett.* **1996**, *37*, 1169–1172.
16. Kluger, R.; Taylor, S. Mechanisms of carbonyl participation in phosphate ester hydrolysis and their relationship to mechanisms for the carboxylation of biotin. *J. Am. Chem. Soc.* **1991**, *113*, 996–1001.
17. Taylor, S.; Kluger, R. Hydrolysis of methylacetoin ethyl phosphate. Competing pathways for carbonyl hydrate participation in a model for biotin carboxylation. *J. Am. Chem. Soc.* **1993**, *115*, 867–871.
18. Sekine, M.; Nakanishi, T. Facile Synthesis of 3'-O-methylthymidine and 3'-deoxythymidine and related deoxygenated thymidine derivative: A new method for



- selective deoxygenation of secondary hydroxy groups. *J. Org. Chem.* **1990**, *55*, 924–928.
19. Koser, G.F.; Chen, K.; Huang, Y.; Summers, C.A. Oxyphosphorylation of carbon with phosphoric acid and p-(difluoroiodo) toluene: Synthesis of tris-ketol phosphates and their conversion into lithium bis-ketol phosphates. *J. Chem. Soc., Perkins Trans.* **1994**, *1*, 1375–1376.
  20. Weislow, O.W.; Kiser, R.; Fine, D.; Bader, J.; Shoemaker, R.H.; Boyd, M.R. New soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. *J. Natl. Cancer Inst.* **1989**, *81*, 577–586.
  21. Chu, C.K.; Schinazi, R.F.; Arnold, B.H.; Cannon, D.L.; Doboszewski, B.; Bhadti, V.B.; Gu, Z. Comparative activity of 2',3'-saturated and unsaturated pyrimidine and purine nucleosides against human immunodeficiency virus type 1 in peripheral blood mononuclear cells. *Biochem. Pharmacol.* **1988**, *37*, 3543–3548.
  22. Baba, M.; Pauwels, R.; Herdewijn, P.; De Clercq, E.; Desmyter, J.; Vandeputte, M. Both 2',3'-dideoxythymidine and its 2',3'-unsaturated derivative (2'3-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro. *Biochem. Biophys. Res. Commun.* **1987**, *142*, 128–134.
  23. Matthes, E.; Lehmann, C.; Scholz, D.; von Janta-Lipinski, M.; Gaerter, K.; Rosenthal, H.A.; Langen, P. Inhibition of HIV-associated reverse transcriptase by sugar modified derivatives of thymidine 5'-triphosphate in comparison to cellular DNA polymerases alpha and beta. *Biochem. Biophys. Res. Commun.* **1987**, *148*, 78–85.
  24. Koser, G.F.; Huang, Y.; Chen; Calvo, K.C. Synthesis and anti-HIV-1 activity of bis-ketol AZT monophosphates. *J. Chem. Soc., Perkin Trans.* **1995**, *1*, 299–302.

Received July 1, 2003

Accepted December 31, 2003



Copyright of Nucleosides, Nucleotides & Nucleic Acids is the property of Marcel Dekker Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.

Copyright of Nucleosides, Nucleotides & Nucleic Acids is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.